This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

India Healthcare, Regulatory and Reimbursement Landscape Report 2019 - ResearchAndMarkets.com

March 7, 2019

DUBLIN--(BUSINESS WIRE)--Mar 7, 2019--The “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India” report has been added to ResearchAndMarkets.com’s offering.

Indian Pharmaceutical Market to Reach $56 billion in 2020.

Driven by the country’s growing economy and population income, the Indian pharmaceutical market will increase significantly from approximately $21 billion in 2013 to $56 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 15%, forecasts research and consulting firm The authors.

According to the company’s latest report*, the medical device sector will also experience steady growth from $7.5 billion in 2013 to $15.3 billion in 2020, at a CAGR of 11%. In 2012, the main segments were ophthalmic devices (38.3%), In-Vitro Diagnostics devices (9%), hospital supplies (8.9%) and cardiovascular devices (8.1%).

Joshua Owide, Director of Healthcare Industry Dynamics, says: India is an emerging healthcare market that has remained unsaturated due to the limited penetration of healthcare insurance and poor access to healthcare facilities, especially in rural areas. However, an increasing demand for high-quality services, affordability, and a growing medical tourism industry will provide the necessary momentum for the growth of the pharmaceutical market.

Still, the lack of transparency in the Indian drug regulatory system and weak patent laws are a major challenge for foreign multinational companies attempting to enter or expand in the Indian healthcare market.

In order to increase transparency in the regulatory system, the Ministry of Health and Family Welfare is planning to introduce a bill into parliament in 2013, to create the Central Drug Authority (CDA), which will replace the current Central Drug Standard Control Organization. Once the CDA is formed, it will greatly improve the regulatory environment for pharmaceuticals, medical devices and clinical trials, says Owide.

However, there is also a need for India to improve its healthcare infrastructure in rural areas and expand its universal health coverage, since 80.6% of the population was not covered by any form of health insurance in 2012 - a factor which could hinder further growth of the market.

Key Topics Covered:

  1. Executive Summary
  2. Overview of Pharmaceutical Market
  3. Overview of Medical Device Market
  4. Deals Analysis
  5. Porter’s Five Forces Model
  6. Market Access
  7. Country Healthcare Landscape
  8. Opportunities and Challenges
  9. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2z5ncg/india_healthcare?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190307005869/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Managed Care



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/07/2019 05:08 PM/DISC: 03/07/2019 05:08 PM